NEW YORK (GenomeWeb) – Biocept today announced a new collaboration with University of California, San Diego Moores Cancer Center aimed at determining the clinical utility of the company's liquid biopsy technology in detecting biomarkers present in circulating tumor cells and cell-free DNA in the blood of non-small cell lung cancer patients.

Biocept's OncoCEE LU platform and CEE-Selector technology allow highly sensitive, quantitative blood-based detection of cancer mutations, which can be used by clinicians to inform personalized treatment decisions based on genomic information.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The ancestors of the Arizona bark scorpion and other scorpions and spiders underwent whole-genome duplication, KJZZ reports.

A cryptographic approach could help researchers keep genomic data private while researchers analyze it, Scientific American reports.

Andy Page, the former president of 23andMe, has joined a diabetes-management startup, according to CNBC.

In Cell this week: regulatory changes in pancreatic cancer, metabolic shifts in Alzheimer's disease, and more.